Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-186
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TAK-186 is a conditionally active bispecific T-cell engager (TCE) designed to target both the epidermal growth factor receptor (EGFR) and CD3 on cytotoxic T lymphocytes. It is engineered using COBRA (Conditional Bispecific Redirected Activation) technology to remain inactive in healthy tissues and become activated within the tumor microenvironment through protease-mediated cleavage. Upon activation, TAK-186 dimerizes and binds simultaneously to EGFR on tumor cells and CD3 on T-cells, redirecting T-cell cytotoxicity specifically toward EGFR-expressing cancer cells. This mechanism aims to enhance anti-tumor efficacy while minimizing off-tumor toxicity. The drug is being developed primarily for advanced or metastatic solid tumors that are unresectable or inoperable[4][6][7][8][10].
- Other names
- EGFR/CD3-targeting T-cell engaging molecule TAK-186
02
Targets
CD3 (T-cell surface glycoprotein CD3)EGFRvIII (Epidermal growth factor receptor variant III)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on TAK-186.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-186.